§ N° III · Dosage
CJC-1295 Dosage in the Research Literature
The Phase I ladder, the rodent characterization doses, the compounding-pharmacy protocols, and what each register can and cannot tell you.
Fig N° IV · Phase I dose ladder · Teichman 2006
Table N° I · Published Phase I dose ladder
| Dose | Route | Reported GH elevation | Reported IGF-1 elevation |
|---|---|---|---|
| 30 µg/kg | Subcutaneous | ~2–4× baseline | ~1.5× baseline |
| 60 µg/kg | Subcutaneous | ~4–6× baseline | ~2× baseline |
| 125 µg/kg | Subcutaneous | ~6–8× baseline | ~2.5× baseline |
| 250 µg/kg | Subcutaneous | ~8–10× baseline | ~3× baseline |
Single-dose ranges from Teichman 2006 in healthy adults. IGF-1 elevation persisted nine to eleven days after a single dose; repeat dosing extended cumulative elevation to twenty-eight days.
§ N° I
The published Phase I ladder
CJC-1295 dosage in the published research begins with one trial. Teichman 2006 administered single subcutaneous doses of 30, 60, 125, and 250 µg/kg of CJC-1295 with DAC to healthy adults in a Phase I dose-escalation design [1]. Across the four doses, mean plasma growth-hormone rose 2- to 10-fold in a dose-dependent fashion, and mean plasma IGF-1 rose 1.5- to 3-fold for nine to eleven days [1][2].
No subsequent human trial has expanded the dose range or characterized chronic-dose response in detail. Repeat-dose subgroups in the Teichman protocol — administered every one or two weeks — produced cumulative IGF-1 elevation that remained above baseline for up to twenty-eight days [2]. The Phase I record stops there. There is no Phase II dose-finding study in any indication that has been published in the peer-reviewed literature beyond the halted 2006 ConjuChem HIV-lipodystrophy trial, for which detailed dose information was not made public [13].
§ N° II
Doses used in published research
Doses used in published research
Phase I human trials used 30, 60, 125, and 250 µg/kg single subcutaneous doses (Teichman 2006) [1]. Rodent receptor-characterization studies used low-microgram intravenous or subcutaneous boluses (Jetté 2005) [4]. GHRH-knockout mouse rescue used once-daily subcutaneous DAC variant (Alba 2006) [5]. Compounding-pharmacy protocols cited in the gray literature run 100-300 µg total daily for the no-DAC variant and weekly 1-2 mg for the DAC variant — these are protocol claims, not research-validated regimens [12].
§ N° III
Administration in research settings
Administration in research settings
Subcutaneous injection in all published human trials [1]. Rodent studies used both subcutaneous and intraperitoneal routes; the foundational Jetté 2005 receptor work also used intravenous administration in rats to characterize the albumin-bioconjugate pharmacokinetics directly [4]. The lyophilized peptide is reconstituted with bacteriostatic water in research handling; specific reconstitution volumes depend on vial mass and the intended concentration of the working solution.
§ N° IV
Dosing frequency
Dosing frequency
With DAC: weekly in the Phase I trial, supported by the multi-day half-life [1][2]. Without DAC (modified GRF 1-29): gray-literature protocols dose one to three times daily because the half-life is approximately thirty minutes and any sustained GH-axis effect requires repeated stimulation [12]. The biological rhythm reflects the molecule: the DAC variant raises the GH baseline; the no-DAC variant produces brief pulses.
§ N° V
Reconstitution in published protocols
Reconstitution in published protocols
Lyophilized peptide is reconstituted with bacteriostatic water in research settings. Specific volumes depend on the vial mass and intended concentration; this is laboratory handling, not a clinical prescription. The Phase I record (Teichman 2006) does not publish a reconstitution SOP because reconstitution is upstream of trial administration — it is the standard handling of a lyophilized injectable peptide and not part of the dosing endpoint itself [1].
§ N° VI
The compounding-pharmacy literature, marked as gray
Compounding-pharmacy dosing protocols for CJC-1295 — typically the no-DAC variant or 'CJC-1295 + ipamorelin' formulations — circulate widely in clinic marketing, compounding-pharmacy product sheets, and direct-to-consumer education. Common citations include 100-300 µg total daily for the no-DAC variant (split into one to three injections) and 1-2 mg weekly for the DAC variant [12].
These are not research-validated regimens. They are protocol claims, generated and circulated within the compounding-pharmacy ecosystem, and not derived from any published trial. The peer-reviewed Phase I doses (30, 60, 125, 250 µg/kg) and the compounding-pharmacy daily-total figures occupy different epistemic registers and should not be conflated. On this page they are rendered in different rules to make the distinction visible at a glance.
§ N° VII
What the research-dose record does not say
The published Phase I literature does not say what dose is 'effective' for body composition, anti-aging, sleep, recovery, or any clinical endpoint. It says what dose produces what pharmacodynamic effect on mean plasma GH and IGF-1 in healthy adults [1][2]. Clinical dose-finding belongs to Phase II and III work that has not been completed for CJC-1295.
The pharmacy dossier renders the doses that exist; it does not invent the doses that do not. The reader who wants a clinical dose recommendation will not find one here because none exists in the public record.